Effect of oral immunotherapy of nuts in the treatment of type 1 allergy

Determination of the effect of oral immunotherapy of nuts in the treatment of patients with type 1 allergy after eating nuts

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240121060754N1

Enrollment

Registered

2024-05-06

Start date

2023-09-23

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 allergy with food. Dermatitis due to ingested food

Interventions

Intervention group: patients are subjected to immunotherapy. Desensitization is done for different people for four types of nuts: walnut, pistachio, hazelnut and almond. Depending on the severity of t

Eligibility

Sex/Gender

All

Age

4 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with type 1 allergy after eating nuts

Exclusion criteria

Exclusion criteria: Patients with cardiovascular diseases, diabetes Patients with skin symptoms of chronic eczema or active allergic diseases such as asthma, allergic rhinitis and uncontrolled active atopic dermatitis

Design outcomes

Primary

Measure	Time frame
Allergy symptoms. Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: Questionnaire and visit.;CRD test (Component-resolved diagnosis). Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: Questionnaire and visit.;Skin prick test. Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: Questionnaire and visit.;Specific antibody test (sIegE). Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: Questionnaire and visit.;Total IgE. Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: blood test.	—

Measure

Time frame

Allergy symptoms. Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: Questionnaire and visit.;CRD test (Component-resolved diagnosis). Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: Questionnaire and visit.;Skin prick test. Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: Questionnaire and visit.;Specific antibody test (sIegE). Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: Questionnaire and visit.;Total IgE. Timepoint: first visit - 4 to 6 months after treatment. Method of measurement: blood test.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedeh Samaneh Asefi

Iran University of Medical Sciences

Asefi_samane@yahoo.com+98 21 6435 2528

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026